CIGB 300

DB16464InvestigationalProtein Based Therapies

CIGB-300, is under investigation in clinical trials for its potential to treat various conditions, including NCT01639638 (recurrent and nonrecurrent condyloma) and NCT01639625 (squamous cell carcinoma and adenocarcinoma of the cervix).

Mechanism: CIGB 300 is a peptide that inhibits protein casein kinase 2 (CK2) activity. It binds to the phospho-acceptors of CK2 substrates, preventing their phosphorylation by CK2. It is currently being investigated as an anti-cancer drug as CK2 is overexpressed in numerous cancers.
Curator reviewed
Also known as: P15-Tat
Code names: CIGB 300

Resolves to

Compound

UNIIX6HMT2EDH9CAS1072877-99-6

Targets

P68400CSNK2A1P06748NPM1

What you can answer from here — as of July 08, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with CIGB 300, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account